Logo Image
Opinion|Videos|November 5, 2024

Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

This episode examines the management of ILD/pneumonitis associated with TROP2-directed ADCs in patients with advanced NSCLC and strategies for mitigating these risks, addresses hematologic toxicities related to docetaxel, and discusses the improved tolerability and lower incidence of severe treatment-emergent adverse events with Dato-DXd compared with docetaxel.

Episodes in this series

Video content above is prompted by the following:

  • Have you observed ILD/pneumonitis associated with a TROP2-directed ADC among your patients with progressive, later-stage, or metastatic NSCLC either in practice or in the context of a clinical trial? 
  • In your opinion, what are the most effective mitigation or prevention strategies that you follow to avoid precluding use of such therapy?
  • What has been your experience with docetaxel-related hematologic toxicities among patients with advanced or metastatic NSCLC? How do you manage these toxicities?
  • Are there laboratory threshold values that motivate you to interrupt, reduce, or discontinue dosing?
  • How encouraged are you by the lower overall incidence of grade greater than or equal to 3 treatment-emergent adverse events and improved tolerability with Dato-DXd vs docetaxel (25% vs 41%)? What is your experience with toxicity management of Dato-DXd?

Related to this article

View more